All stock lists
Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
Healthcare · Biotechnology
23.52+0.00 (+0.00%)
Insider Score
––Not scored
CYCN Insider Score
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
CYCN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 1.02 M | 875.00 K | 93.00 K | 81.00 K |
| Revenue Growth (YoY) | -100.00 % | -100.00 % | -43.24 % | 351.03 % | — | — |
| Cost of Revenue | 0.00 | 730.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -730.00 K | 1.02 M | 875.00 K | 93.00 K | 81.00 K |
| SG&A Expense | 1.77 M | 2.48 M | 1.34 M | 1.53 M | 1.71 M | 1.50 M |
| R&D Expense | 0.00 | 730.00 K | 519.00 K | 348.00 K | 56.00 K | 36.00 K |
| Operating Expenses | 1.77 M | 2.48 M | 1.86 M | 1.88 M | 1.76 M | 1.54 M |
| Operating Income | -1.77 M | -3.21 M | -838.00 K | -1.01 M | -1.67 M | -1.46 M |
| Pretax Income | -1.75 M | -3.18 M | -799.00 K | -976.00 K | -324.00 K | -1.43 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.75 M | -3.18 M | -799.00 K | -976.00 K | -324.00 K | -1.43 M |
| EPS (Basic) | -2.87 | -5.32 | -1.75 | -2.10 | -0.77 | -3.92 |
| EPS (Diluted) | -2.87 | -5.32 | -1.75 | -2.10 | -0.77 | -3.92 |
| Shares Outstanding | 607.29 K | 600.71 K | 460.71 K | 460.71 K | 438.71 K | 365.14 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.